New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
16:10 EDTAERIAerie Pharmaceuticals reports Q4 GAAP EPS (62c), consensus (25c)
Included in the $10.3M net loss and the (62c) EPS are non-cash charges totaling $4.9M, of which $1.3M represents stock-based compensation expense included in operating expenses. With these non-cash items excluded, the adjusted operating expenses of $5.4M include adjusted research and development expenses of $3.0M and adjusted general and administrative expenses of $2.4M. In addition to the $1.3M stock-based compensation expense, the $4.9M in non-cash charges include a $2.7M extinguishment loss related to the conversion of the Company’s outstanding convertible promissory notes to common equity upon the closing of the IPO and $900,000 in accrued interest and amortization expense related to the Company’s notes that were converted to common equity upon the closing of the IPO.
News For AERI From The Last 14 Days
Check below for free stories on AERI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
06:10 EDTAERIAerie Pharmaceuticals receives $125M investment from Deerfield Management
Subscribe for More Information
06:05 EDTAERIAerie Pharmaceuticals issues $125M in convertible notes to Deerfield Management
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use